SCHEMBL16636034

SCHEMBL16636034

O=C(O)C1CCCCC1c1csc(C2CCOCC2)n1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
USP2 O75604 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
CASP6 P55212 1/20 0.34
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
UCHL1 P09936 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
CNR2 P34972 2/20 0.31
S1PR3 Q99500 1/20 0.30
GRM4 Q14833 1/20 0.30
TMIGD3 P0DMS9 1/20 0.30
ADORA1 P30542 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636392 0.85 SLC6A2 (0.39) ALDH1A1SMN1; SMN2UCHL1CNR2TMIGD3
SCHEMBL16636390 0.85 SLC6A2 (0.39) ALDH1A1SMN1; SMN2UCHL1CNR2TMIGD3
SCHEMBL16636090 0.82 ALDH1A1 (0.37) ALDH1A1USP2KMT2AMEN1POLB
SCHEMBL16636015 0.73
SCHEMBL3551574 0.72 CASP8 (0.47) ALDH1A1KDM4E
SCHEMBL16636564 0.68 SLC6A2 (0.39) ALDH1A1SMN1; SMN2CNR2TMIGD3ADORA1
SCHEMBL16636565 0.68 SLC6A2 (0.39) ALDH1A1SMN1; SMN2CNR2TMIGD3ADORA1
SCHEMBL16635958 0.68 LMNA (0.50) ALDH1A1KMT2AMEN1POLBKDM4E
SCHEMBL16635682 0.68 FNTA (0.44) ALDH1A1USP2KMT2AMEN1POLB
SCHEMBL26979851 0.68 HTR2B (0.38) ALDH1A1SMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ ALDH1A1 4582/4885USP2 339/4885KMT2A 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.